OncoMatch/Clinical Trials/NCT06494371
A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
Is NCT06494371 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies LCAR-HL30 cells for hodgkin's lymphoma.
Treatment: LCAR-HL30 cells — This is a prospective, single-arm, open-label, exploratory clinical study of LCAR-HL30 in adult subjects with relapsed/refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Biomarker criteria
Required: CD30 positive expression
positive CD30 expression
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: car-t cell therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify